. 2022; 39(4): 237-244 | DOI: 10.4274/tjh.galenos.2022.2022.0045 | |||
Kronik Myeloid Löseminin Klonal Evolüsyonunda Sitogenetik Aberasyonların Etkisi: 450 Türk Hastadan Oluşan Kohort Çalışmasında Tek Merkez DeneyimiSevgi Işık1, Gülçin Günden1, Hava Üsküdar Teke2, Olga Meltem Akay3, Nur Oğuz Davutoğlu2, Vahap Aslan4, Mustafa Karagülle5, Hülya Özen7, Oğuz Çilingir1, Sevilhan Artan1, Beyhan Durak Aras61Eskişehir Osmangazi University Faculty of Medicine, Department of Medical Genetics, Eskişehir, Turkey2Eskişehir Osmangazi University Faculty of Medicine, Department of Internal Diseases, Division of Hematology, Eskişehir, Turkey 3Koç University Faculty of Medicine, Department of Hematology, İstanbul, Turkey 4Private Umit Hospitals, Clinic of Hematology, Eskişehir, Turkey 5Yunus Emre State Hospital, Clinic of Hematology, Eskişehir, Turkey 6Eskişehir Osmangazi University Faculty of Medicine, Department of Medical Genetics, Eskişehir, Turkey; Eskişehir Osmangazi University, Translational Medicine Research and Clinical Center, Eskişehir, Turkey 7University of Health Sciences Turkey, Gülhane Faculty of Medicine, Department of Medical Informatics, Ankara, Turkey Amaç: Kronik myeloid lösemi (KML), t(9;22) ile karakterize olan, Ph(+) ve (-) klonlarda sitogenetik aberasyonların gelişebildiği bir lösemi tipi olarak bilinmektedir. Bu aberasyonlar klonal evolüsyon ve tedaviye bağlı gelişmekte olup, prognostik etkileri olduğu bilinmektedir. Literatürde; tedavi yanıtı, toplam sağkalım (OS), hastalık evresi, tam sitogenetik yanıt (TSY) ve majör moleküler yanıt (MMY) gibi prognostik parametreler üzerine olan etkileri açısından bu anomaliler majör ve minör yolak anomalileri olarak gruplandırılmaktadır. Majör yolak anomalilerinin minör yolak anomalilerine göre prognozu olumsuz yönde etkilediği belirtilmektedir. Biz de, Ph(+) ve (-) klonda saptanan sitogenetik anomalilerin sıklığını ve prognostik etkisini araştırmayı amaçladık. The Impact of Cytogenetic Aberrations in the Clonal Evolution of Chronic Myeloid Leukemia: A Single-Center Experience Among 450 Turkish Patients (Cohort Study)Sevgi Işık1, Gülçin Günden1, Hava Üsküdar Teke2, Olga Meltem Akay3, Nur Oğuz Davutoğlu2, Vahap Aslan4, Mustafa Karagülle5, Hülya Özen7, Oğuz Çilingir1, Sevilhan Artan1, Beyhan Durak Aras61Eskişehir Osmangazi University Faculty of Medicine, Department of Medical Genetics, Eskişehir, Turkey2Eskişehir Osmangazi University Faculty of Medicine, Department of Internal Diseases, Division of Hematology, Eskişehir, Turkey 3Koç University Faculty of Medicine, Department of Hematology, İstanbul, Turkey 4Private Umit Hospitals, Clinic of Hematology, Eskişehir, Turkey 5Yunus Emre State Hospital, Clinic of Hematology, Eskişehir, Turkey 6Eskişehir Osmangazi University Faculty of Medicine, Department of Medical Genetics, Eskişehir, Turkey; Eskişehir Osmangazi University, Translational Medicine Research and Clinical Center, Eskişehir, Turkey 7University of Health Sciences Turkey, Gülhane Faculty of Medicine, Department of Medical Informatics, Ankara, Turkey Objective: Objective: Chronic myeloid leukemia (CML) is a clonal hematologic disorder characterized by t(9;22) translocation, in which cytogenetic aberrations can occur in Ph(+) and (-) clones. These aberrations develop due to clonal evolution as well as treatment and they have prognostic significance. They are grouped as major and minor route anomalies in terms of their effects on prognostic parameters, such as treatment response, overall survival (OS), disease stage, complete cytogenetic response (CCyR), and major molecular response (MMR). It is stated that major route anomalies have unfavorable prognostic effects compared to minor route anomalies. We aimed to investigate the frequency and prognostic effects of cytogenetic anomalies detected in Ph(+) and (-) clones. Sevgi Işık, Gülçin Günden, Hava Üsküdar Teke, Olga Meltem Akay, Nur Oğuz Davutoğlu, Vahap Aslan, Mustafa Karagülle, Hülya Özen, Oğuz Çilingir, Sevilhan Artan, Beyhan Durak Aras. The Impact of Cytogenetic Aberrations in the Clonal Evolution of Chronic Myeloid Leukemia: A Single-Center Experience Among 450 Turkish Patients (Cohort Study). . 2022; 39(4): 237-244 Sorumlu Yazar: Gülçin Günden, Türkiye |
|